Table 2.

The clinical characteristics of the affected hips of all ONFH patients in this study.

	LPFH group	Non-LPFH group
n (hips)	376	152
Duration of symptoms, months	6.5 ± 7.1	5.2 ± 9.4
CJFH classification (hips)	M,81; C,184; L1,111	L2,57; L3,95
ARCO stage lesions (hips)
Stage I	112	25
Stage II	208	38
Stage III	56	89
Medical history
Steroid intake	192	85
Alcoholic abuse	71	25
Negative	113	42
Length of follow-up (months)	14.5 ± 8.3	15.2 ± 7.8

Note: CJFH: China-Japan Friendship Hospital; ARCO: the Association Research Circulation Osseous.